S&P 500   4,981.95 (+0.13%)
DOW   38,607.44 (+0.11%)
QQQ   423.50 (-0.89%)
AAPL   181.52 (-0.02%)
MSFT   399.32 (-0.86%)
META   465.75 (-1.17%)
GOOGL   142.19 (+0.76%)
AMZN   168.22 (+0.68%)
TSLA   193.73 (-0.02%)
NVDA   671.27 (-3.35%)
NIO   6.01 (+0.84%)
AMD   163.86 (-1.10%)
BABA   75.41 (+3.10%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.95 (+0.30%)
CGC   3.44 (-2.82%)
GE   148.48 (-0.09%)
DIS   107.50 (-1.77%)
AMC   4.57 (-1.93%)
PFE   27.57 (-0.07%)
PYPL   57.41 (-2.08%)
XOM   104.52 (+1.72%)
S&P 500   4,981.95 (+0.13%)
DOW   38,607.44 (+0.11%)
QQQ   423.50 (-0.89%)
AAPL   181.52 (-0.02%)
MSFT   399.32 (-0.86%)
META   465.75 (-1.17%)
GOOGL   142.19 (+0.76%)
AMZN   168.22 (+0.68%)
TSLA   193.73 (-0.02%)
NVDA   671.27 (-3.35%)
NIO   6.01 (+0.84%)
AMD   163.86 (-1.10%)
BABA   75.41 (+3.10%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.95 (+0.30%)
CGC   3.44 (-2.82%)
GE   148.48 (-0.09%)
DIS   107.50 (-1.77%)
AMC   4.57 (-1.93%)
PFE   27.57 (-0.07%)
PYPL   57.41 (-2.08%)
XOM   104.52 (+1.72%)
S&P 500   4,981.95 (+0.13%)
DOW   38,607.44 (+0.11%)
QQQ   423.50 (-0.89%)
AAPL   181.52 (-0.02%)
MSFT   399.32 (-0.86%)
META   465.75 (-1.17%)
GOOGL   142.19 (+0.76%)
AMZN   168.22 (+0.68%)
TSLA   193.73 (-0.02%)
NVDA   671.27 (-3.35%)
NIO   6.01 (+0.84%)
AMD   163.86 (-1.10%)
BABA   75.41 (+3.10%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.95 (+0.30%)
CGC   3.44 (-2.82%)
GE   148.48 (-0.09%)
DIS   107.50 (-1.77%)
AMC   4.57 (-1.93%)
PFE   27.57 (-0.07%)
PYPL   57.41 (-2.08%)
XOM   104.52 (+1.72%)
S&P 500   4,981.95 (+0.13%)
DOW   38,607.44 (+0.11%)
QQQ   423.50 (-0.89%)
AAPL   181.52 (-0.02%)
MSFT   399.32 (-0.86%)
META   465.75 (-1.17%)
GOOGL   142.19 (+0.76%)
AMZN   168.22 (+0.68%)
TSLA   193.73 (-0.02%)
NVDA   671.27 (-3.35%)
NIO   6.01 (+0.84%)
AMD   163.86 (-1.10%)
BABA   75.41 (+3.10%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.95 (+0.30%)
CGC   3.44 (-2.82%)
GE   148.48 (-0.09%)
DIS   107.50 (-1.77%)
AMC   4.57 (-1.93%)
PFE   27.57 (-0.07%)
PYPL   57.41 (-2.08%)
XOM   104.52 (+1.72%)
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

$11.14
+0.04 (+0.36%)
(As of 02/20/2024 ET)
Today's Range
$11.14
$11.55
50-Day Range
$10.73
$12.28
52-Week Range
$10.39
$16.91
Volume
276,032 shs
Average Volume
238,631 shs
Market Capitalization
$20.16 billion
P/E Ratio
28.46
Dividend Yield
3.05%
Price Target
N/A

Astellas Pharma MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.97mentions of Astellas Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
100.00%
From $0.31 to $0.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.70 out of 5 stars


ALPMY stock logo

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

ALPMY Stock News Headlines

Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Astellas Makes Announcement about Management Structure
An Opportunity to Capitalize on Theme Parks
NASDAQ is Aiming to Conquer One of the Biggest Markets in the World!
Astellas Pharma Announces Collaboration With Mass General Brigham
Astellas Pharma Inc. ADR
See More Headlines
Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/21/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,484
Year Founded
1923

Profitability

Net Income
$742 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.24 billion
Cash Flow
$1.36 per share
Book Value
$6.27 per share

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$20.16 billion
Optionable
Not Optionable
Beta
0.34

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Naoki Okamura BSc (Age 62)
    President, CEO & Director
    Comp: $971.78k
  • Mr. Atsushi Kitamura
    Chief Financial Officer
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 57)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Collette Taylor (Age 61)
    Senior Vice President of Human Resources
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive

Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Astellas Pharma was last updated on Tuesday, February 20, 2024 at 9:55 PM.

Pros

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • Astellas Pharma Inc. offers a diverse portfolio of pharmaceutical products, including XTANDI for prostate cancer, XOSPATA for relapsed or refractory acute myeloid leukemia, and PADCEV for metastatic urothelial cancer.
  • The company has ongoing research collaborations and partnership agreements, such as with Vivtex Corporation and Roche Diabetes Care Japan Co., Ltd., indicating a commitment to innovation and growth.
  • Despite the recent setback with the FDA declining to approve its gastric cancer drug, Astellas Pharma Inc. has not faced concerns related to its clinical data, which could indicate strong research and development capabilities.
  • Astellas Pharma Inc. has a long-standing history since its founding in 1923, providing a sense of stability and experience in the pharmaceutical industry.
  • Investors may find Astellas Pharma Inc. stock price attractive based on recent market trends and financial performance, offering a potential opportunity for capital appreciation.

Cons

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • The recent FDA decision declining to approve Astellas' gastric cancer drug could impact the company's revenue projections and future growth potential in the oncology market.
  • Market volatility and regulatory challenges in the pharmaceutical industry may pose risks to Astellas Pharma Inc.'s stock performance and overall financial stability.
  • Competition from other pharmaceutical companies developing similar treatments could affect Astellas Pharma Inc.'s market share and pricing strategies.
  • Uncertainties surrounding global healthcare policies and regulations may introduce additional complexities for Astellas Pharma Inc.'s operations and market expansion efforts.
  • Investors should carefully monitor any updates on Astellas Pharma Inc.'s pipeline developments and regulatory interactions to assess potential risks and opportunities in the pharmaceutical sector.














ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALPMY shares.
View ALPMY analyst ratings
or view top-rated stocks.

How have ALPMY shares performed in 2024?

Astellas Pharma's stock was trading at $11.90 at the beginning of 2024. Since then, ALPMY shares have decreased by 6.4% and is now trading at $11.14.
View the best growth stocks for 2024 here
.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 68,200 shares, a drop of 57.1% from the December 31st total of 159,100 shares. Based on an average daily trading volume, of 310,800 shares, the short-interest ratio is presently 0.2 days.
View Astellas Pharma's Short Interest
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its earnings results on Wednesday, November, 1st. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.18. The company earned $2.71 billion during the quarter. Astellas Pharma had a net margin of 0.08% and a trailing twelve-month return on equity of 6.23%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.34 per share and currently has a dividend yield of 3.02%.

When did Astellas Pharma's stock split?

Astellas Pharma shares split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were payable to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
This page (OTCMKTS:ALPMY) was last updated on 2/21/2024 by MarketBeat.com Staff